Optieum Biotechnologies Inc. is a pre-clinical stage biotechnology company committed to developing innovative scFv antibody-based therapies for the treatment of patients with cancers.
Our proprietary platform technology, Eumbody System™, enables to develop and detect a scFv-based product candidates that specifically bind to, and modulate to optimize the immune-cell function for oncology targets.
We are committed to help patients with severe diseases by bringing life-changing therapies to the patients in need.
Optieum Biotechnologies’s Eumbody System™ is a proprietary platform technology for the development of next-generation scFv antibody.
Our technology enables to generate the new scFv expressing CAR-T cells with greater proliferation capacity and longevity, enabling superior reactivity against advanced tumors and minimized adverse effects.
We are open for a partnership to jointly develop a next generation immuno-oncology products.